TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities of Botulinum Toxin A (BoNT-A) in Adult Patients Suffering From Upper Limb Spasticity After Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject able to comply with the protocol~* Provision of written informed consent prior to collecting the data~* Male or female patients of 18 years or older~* Presenting with upper limb spasticity after stroke for which treatment with botulinum toxin A is indicated~Exclusion Criteria:~* The subject has already been included in this survey~* Patients who already received BoNT-A treatment for upper limb spasticity~* Patients with known intolerance for BoNT-A~* Subjects unable to comply with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Single Blind Randomized Study to Determine the Sensitivity and Specificity of 2 Non-invasive Markers of Early Coronary Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age 20 to 70 years old~* angiogram within past 12 weeks~* stable during post angio period~* willing to provide informed consent~Exclusion Criteria:~* previous eye surgery including cataract surgery~* previous ophthalmologic disorders~* previous surgeries involving ears or ear lobes

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Presence of coronary disease (Type: None): All patients with or without coronary disease who are followed in coronary clinics or wards
- coronary disease (Type: None): Is coronary disease associated with tortuosity of vessels Patients seen in cardiology clinics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have signed a General Consent form approving use of their residual blood samples for research purposes (applicable at CHUV only)~* Patients who have signed a consent allowing the use of their residual sample (Restprobenerklärung) (applicable at MUI, only)~* Patients over the age of 18 years (\>18)~* Patients with bacteremia considered to be due to E. coli or K. pneumoniae~* Patients whose positive blood cultures were not older than 24 hours at the time of AST start~Exclusion Criteria:~* Patients with documented refusal of the use of biological material for research purposes (applicable at CHUV, only)~* Patients with polymicrobial bacteremia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed recurrent or progressive supratentorial glioblastoma or anaplastic astrocytoma~* Measurable disease by MRI or CT scan~* No gliomatosis cerebri, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma~* Concurrent registration for the System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.) program~PATIENT CHARACTERISTICS:~Age:~* Over 18~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* WBC greater than 4,000/mm\^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* Bilirubin less than 2.0 mg/dL~Renal:~* Creatinine less than 1.6 mg/dL~Other:~* No other concurrent malignancy except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 2 methods of effective contraception 1 month prior to, during, and for 1 month after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No more than 2 prior chemotherapy regimens in adjuvant or metastatic setting~* At least 4 weeks since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* Concurrent anticonvulsants allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Moderate to Persistent Asthma in the Obese Subject

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* moderate persistent asthma as defined daily symptoms, nocturnal awakenings \>1 time/week but not daily, daily short-acting beta agonist usage~* pre-bronchodilator Force expiratory volume (FEV1)\>55% but \<90%.~* Subjects must be on controller therapy for asthma with ICS for at least one month prior to enrollment.~* methacholine testing that causes a drop in the FEV1 of 20% (8mg/ml off ICS or 16mg/ml) on ICS within 6 months prior to entry~* physician diagnosis of asthma for at least one year prior to study enrollment.~* Obesity defined as BMI greater than 30.~* subjects must have an Asthma Control Questionnaire (ACQ) score \>1.25 on the Juniper Asthma Control Questionnaire (indicating poor asthma control),~* require daily medications for asthma and be compliant with study related medications.~Exclusion Criteria:~* Subjects must not have been intubated in the last 5 years or unstable asthma symptoms resulting in significant loss or work or school~* upper or lower respiratory tract infection within 1 month of the study~* use of antibiotics within 4 weeks of the study~* use of oral glucocorticoids within 4 weeks~* use of theophylline~* smoking history greater than 10 pack years or any cigarette use within the past two years~* significant non-asthma pulmonary disease or other medical problems~* Subjects planning to undergo gastric bypass surgery within 4 months of the enrollment date will be excluded since weight loss is a potential confounder of asthma control~* Pregnant women will also be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- leukotriene receptor antagonist (LTRA) montelukast (Type: ACTIVE_COMPARATOR): Montelukast (LTRA) administered with moderate dose of inhaled steroid
- Sugar Pill (Type: PLACEBO_COMPARATOR): High dose of inhaled steroid administered with sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 to 79~* Type 2 diabetes, treated only by diet or oral drugs other than metformin~* HbA1c greater than or equal to 7% and less than or equal to 10%~* C-reactive protein greater than or equal to 2 mg/L~Exclusion Criteria:~* Baseline use of metformin or insulin~* Type 1 diabetes, history of ketoacidosis or positive anti-GAD antibody~* History of congestive heart failure requiring drug therapy~* Active liver disease~* Kidney impairment~* Recent initiation or change in dose of statins, fibric acid derivatives, angiotensin receptor blockers, nonsteroidal anti-inflammatory agents, or corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Placebo pill (Type: PLACEBO_COMPARATOR): Placebo pill
- Metformin Pill (Type: ACTIVE_COMPARATOR): Metformin pill
- Insulin Glargine plus placebo pill (Type: ACTIVE_COMPARATOR): Insulin glargine plus placebo pill
- Insulin Glargine plus metformin pill (Type: ACTIVE_COMPARATOR): Insulin Glargine plus metformin pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Human Brain Adaptation to Chronic Pain and Its Effects on Opioid Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-65~2. With and without history of chronic muscle-skeletal pain \*~3. Scheduled to undergo elective abdominal surgery requiring overnight hospital admission~4. Opioid naïve\*\*~5. Willing to comply with study procedures as outlined in the protocol~6. Willing and able to provide informed consent~7. Having an email address and access to a computer or electronic tablet~Exclusion Criteria:~1. Current use of opioids (includes ANY use in past 3 months)~2. Cancer diagnosis~3. Patient presenting the following documented conditions:~Untreated psychosis Current suicidal ideation Current substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Study Arms:
- Chronic pain group (Type: None): post-surgical opioid use measured at 1 day and 1 week.
- No chronic pain (Type: None): post-surgical opioid use measured at 1 day and 1 week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bleeding peptic ulcer: Among patients suspected to have upper GI bleeding based on hematemesis or melena, those with peptic ulcers(Forrest I, IIa and IIb) in whom active bleeding, non-bleeding visible vessels and fresh blood clots are observed on upper GI endoscopy performed within 24 hours after the hospitalization~* patients who achieved primary hemostasis with endoscopic hemostasis procedure via upper GI endoscopy~Exclusion Criteria:~* Patients who refuse endoscopic procedure~* Patients with complications from gastric ulcer that require operative treatment prior to upper GI endoscopic treatment(e.g., gastric outlet obstruction, peptic ulcer perforation)~* Pregnancy~* Patients with serious concurrent diseases such as malignant tumors or end-stage diseases~* History of previous gastrectomy or vagotomy~* Known hypersensitivity to proton pump inhibitors~* Elderly patients~* Epilepsy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rabeprazole sodium (Type: EXPERIMENTAL): Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
- Omeprazole (Type: ACTIVE_COMPARATOR): Intravenous Omeprazole 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have documented human immunodeficiency virus type 1 (HIV-1) infection~* Must be antiretroviral (ARV) treatment-naïve~* Have plasma HIV-1 ribonucleic acid (RNA) less than (\<) 100,000 copies/milliliter (mL) at screening visit~* Have cluster of CD4+ T-cell count (greater than) \>200/ cubic millimeter (mm\^3) at screening visit~* Women of childbearing potential must have a negative serum (beta human chorionic gonadotropin \[beta hCG\]) pregnancy test at screening; and a negative urine (or serum, if required by local regulations) pregnancy test before the first dose of study~Exclusion Criteria:~* History of any primary nucleo(t)side reverse transcriptase inhibitor (N\[t\]RTI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations (if testing performed locally, and results are available), as defined by the current International AIDS (acquired immunodeficiency syndrome) Society-United States (USA) (International Antiviral Society-USA) 2017 guidelines~* Has clinical or laboratory evidence of significantly decreased hepatic function or decompensation, irrespective of liver enzyme levels (hepatic insufficiency)~* Diagnosed with acute viral hepatitis at screening or before baseline~* Infected with Mycobacterium tuberculosis which is likely to require rifampicin-based treatment during the study~* Has a Grade 3 or 4 laboratory abnormality as defined by the Division of AIDS (DAIDS) for Grading the Severity of Adult and Pediatric Adverse Events criteria with the following exceptions unless clinical assessment foresees an immediate health risk to the participant: (a) Preexisting diabetes or with asymptomatic glucose Grade 3 or 4 elevations (b) Asymptomatic triglyceride or cholesterol elevations of Grade 3 or 4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment: Rilpivirine+Combination Therapy (TDF/3TC) (Type: EXPERIMENTAL): The participants will receive antiretroviral treatment of rilpivirine 25 milligram (mg) tablet orally once daily from Day 1 for 48 weeks with a meal to improve absorption. The participants will also receive background combination therapy of 1 tablet orally once daily containing 300 mg tenofovir disoproxil fumarate (TDF) and 300 mg lamivudine (3TC).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Balance Gaming as an Adjunct to Vestibular Rehabilitation Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral vestibular loss~* Uncompensated~* Present for \>6 months~Exclusion Criteria:~* Age \<18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): No Wii balance gaming undertaken
- Wii during vestibular rehab only (Type: ACTIVE_COMPARATOR): To start Wii Balance Gaming from the beginning of vestibular rehabilitation.
- Wii whilst on waiting list and rehab (Type: ACTIVE_COMPARATOR): Wii Balance Gaming whilst on waiting list for vestibular rehabilitation. To continue with Wii Balance Gaming until end of vestibular rehabilitation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Degarelix Trial in Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has given written consent prior to any trial-related activity is performed. (A trial-related activity is defined as any procedure that would not have been performed during the normal management of the patient).~* Has completed the CS35 trial.~Exclusion Criteria:~* Has been withdrawn from the CS35 trial.~* Has had end of trial visit in CS35 prior to approval of the CS35A protocol.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix 240 mg/480 mg (Type: EXPERIMENTAL): None
- Goserelin acetate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI 35-55 Kg/m2~* Fasting Blood glucose \>140mg/dl~* Planned bariatric surgery~* Diabetic Medication (Metformin, Sulfonylurea, Insuline)~Exclusion Criteria:~* Known hypersensitivity against Liraglutid~* Pretreatment DPP-4 Inhibitors or GLP-1 Analogue the last 3 months~* HbA1c \>10%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- GLP-1 (Liraglutide) (Type: ACTIVE_COMPARATOR): Daily subcutaneous injection of Lirglutide over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Daily subcutaneous injection of PL1/PR1 Placebo over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Micropuncture vs. Standard Common Femoral Artery Access

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Patients undergoing left heart or peripheral catheterization through the common femoral artery with anticipated or possible percutaneous coronary or peripheral intervention~Exclusion Criteria:~1. Arterial access obtained through the radial or brachial artery~2. Age less than 18 years~3. Patients with known bleeding diathesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Micropuncture Access (Type: ACTIVE_COMPARATOR): Vascular access using micropuncture needle kit
- Standard 18G vascular access needle (Type: ACTIVE_COMPARATOR): Vascular access using standard 18G needle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Filipino hypertensive subjects ages 18-65 years old whether naive or currently taking any other anti-hypertensive or those on monotherapy using CCBs or ARBs whom they want to shift on a fixed dose combination drug~Exclusion Criteria:~* Patients with contraindications to any of the component of the fixed drug (amlodipine or olmesartan medoxomil) or with malignant or secondary hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Filipino Hypertensive patients (Type: None): Male and Female, 18 to 65 year old Filipino hypertensive patients prescribed by their doctors with Normetec

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval